Cholinergic approaches to the treatment of Alzheimer's disease.
D015761:4-Aminopyridine; D000409:Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000188:drug therapy*; D000631:Aminopyridines / Q000627:therapeutic use; D001115:Arecoline / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D010277:Parasympathomimetics / Q000627:therapeutic use*; D010830:Physostigmine / Q000627:therapeutic use; D010889:Piracetam / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D012107:Research Design; D013388:Succinimides / Q000627:therapeutic use; D013569:Synapses / Q000187:drug effects
D000631:Aminopyridines; D010277:Parasympathomimetics; D011759:Pyrrolidines; D013388:Succinimides; C001886:2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione; D001115:Arecoline; C038672:N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide; D010830:Physostigmine; D015761:4-Aminopyridine; C025293:alaproclate; D000409:Alanine; D010889:Piracetam